Why Does HRT Work Differently for Every Woman? The Genetic Answer

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

If you've heard a friend describe dramatic relief from HRT while your own experience has been flat — or noticed that the same protocol that seemed right on paper is producing effects you didn't expect — you're not imagining a difference that shouldn't exist. The difference is real, and it has a biological explanation. HRT doesn't have a universal response because the biology it engages isn't universal. Every woman who starts a hormone support protocol brings a different genetic architecture to it — a unique set of enzymatic speeds, receptor sensitivities, and clearance capacities that determine what the estrogen actually does once it enters her body. The PlexusDx Precision Peptide Genetic Test maps those variables across 14 pathways, 49 peptides, and 150+ genetic insights, replacing the guesswork with a defined biological starting point.

What "Works Differently" Actually Means

Before exploring why HRT varies, it helps to define the variable outcomes women actually experience:

Symptom response: Some women experience substantial relief from hot flashes, night sweats, sleep disruption, mood instability, and cognitive fog on HRT. Others experience minimal improvement at doses that work well for population averages. Some experience unexpectedly strong estrogenic effects — breast tenderness, bloating, mood changes — at conservative doses that should be well-tolerated.

Dose requirements: The dose at which a woman achieves therapeutic benefit differs significantly between individuals — not because providers are guessing, but because the same circulating estradiol level produces meaningfully different biological effects in different women depending on their receptor sensitivity and metabolic clearance speed.

Side effect profile: The types and intensity of side effects vary in ways that standardized prescribing guidelines can't always predict — because side effects often reflect the metabolic fate of estrogen rather than the estrogen level itself.

Long-term outcomes: Bone density trajectory, cardiovascular markers, and cognitive function on HRT all vary between women — outcomes that are shaped not just by whether someone takes HRT but by the genetic terrain through which the hormone is processed and received over time.

All four of these variability dimensions have partial explanations in dose, delivery route, timing, body composition, and individual health history. But all four also have a foundational genetic explanation that precedes and underlies every other variable — and that genetics is what the Precision Peptide Genetic Test maps.

The Non-Genetic Variables Are Real — But Incomplete

It would be misleading to suggest that genetics explains everything about HRT response variability. Several non-genetic factors are genuinely important and worth acknowledging before arriving at the genetic layer:

Dose and delivery route. Too low a dose produces insufficient estrogenic signal; too high a dose produces excessive effects regardless of genetics. Oral versus transdermal delivery produces different estrogen pharmacokinetics through different hepatic first-pass effects. These are real variables that providers adjust — and they account for some of the variability in individual HRT experiences.

Timing of initiation. Research suggests that the timing of HRT relative to the menopausal transition influences the biological context the estrogen is entering. Initiated closer to the onset of menopause, estrogenic support works within a system still accustomed to estrogen signaling. Initiated well after that transition, the context may have shifted.

Body composition and metabolic health. Adipose tissue is an active site of peripheral aromatization — converting androgens to estrogens. Body composition affects the total estrogen environment into which HRT adds its contribution.

All of these are real. And yet none of them explains why two women with the same dose, the same delivery route, the same timing, and similar body composition can still experience profoundly different outcomes on the same protocol. That remaining variability — the gap that dose and delivery adjustments cannot close — is where genetics lives. It explains the underlying biological individual differences that remain after every non-genetic variable is equalized.

Why Genetics Is the Foundational Explanation

The estrogen biology cascade has four genetically variable layers, and each one shapes a different dimension of HRT response:

How estrogen is converted in Phase 1. CYP1A1 and CYP1B1 determine the ratio of less-reactive 2-OHE2 to more-reactive 4-OHE2 produced from estradiol. High-activity CYP1B1 variants increase 4-OHE2 production — loading more reactive substrate into Phase 2 clearance for every unit of estradiol from any source, including HRT. A woman with high CYP1B1 activity experiences more reactive metabolite burden per milligram of estrogen than a woman with lower CYP1B1 activity at the same dose. Full detail: CYP1A1 and CYP1B1: Estrogen Metabolism Pathways.

How quickly estrogen metabolites are cleared in Phase 2. COMT Val158Met determines the primary methylation clearance rate. MTHFR constrains the SAMe supply that COMT depends on. SULT1A1 provides the independent sulfation backup that compensates when methylation is slow. GSTM1 and GSTT1 backstop the reactive quinones that form when primary clearance is insufficient. Each of these variables is genetically fixed — and each determines how long estrogen metabolites remain biologically active in circulation after the protocol delivers its dose. A woman with slow COMT, impaired MTHFR, low SULT1A1, and null GSTM1 is running all four clearance pathways at reduced capacity simultaneously. Full details: COMT Val158Met and Estrogen Clearance, MTHFR and Methylation: The Women's Hormone Connection, SULT1A1 Sulfation: Estrogen Detox Genetics.

How sensitively tissues read the estrogen signal. ESR1 and ESR2 variants determine how amplified or attenuated the tissue-level response to any given estradiol concentration is — in bone, brain, breast, cardiovascular endothelium, and hypothalamus. Low-sensitivity ESR1 variants mean the same measured estradiol level generates less bone protection, less vasomotor symptom relief, and less mood stabilization at the tissue level than in a high-sensitivity woman. This is why estradiol measurements are an incomplete guide to therapeutic estrogen effect — the receptor sensitivity genetics determine how the measurement translates into biology. Full detail: Estrogen Receptor Genetics: ESR1 and ESR2 Variants.

Across all three layers, genetic variation doesn't just shift outcomes marginally — it determines fundamentally different biological environments in which the same HRT protocol operates. Two women at the same dose, same route, same timing, and same measured estradiol level can be experiencing profoundly different estrogenic biology at the tissue level because their genetics defines the terrain.

The Six Genetic Variables That Matter Most

The Precision Peptide Genetic Test analyzes 6 Reproductive Health insights that together capture the genetic architecture of HRT response. The full synthesis of how these six variables compound and interact is in Genetics of HRT Response: Why Women React Differently. In brief:

CYP1A1 / CYP1B1 — Phase 1 hydroxylation ratio: determines the reactive metabolite burden per unit of estradiol.

COMT Val158Met — primary Phase 2 methylation clearance rate: determines how quickly catechol estrogens are inactivated after Phase 1.

MTHFR C677T / A1298C — upstream SAMe supply: constrains COMT's operational capacity and elevates homocysteine as a monitoring variable.

SULT1A1 Arg213His — independent sulfation clearance: provides backup when methylation is constrained, and shapes the postmenopausal estrone sulfate reservoir.

GSTM1 / GSTT1 null deletions — glutathione backstop: the final enzymatic defense against reactive estrogen quinones when primary clearance routes are under pressure.

ESR1 / ESR2 — receptor sensitivity: determines how powerfully the cleared estrogen signal activates target tissues — the terminal layer where "working" or "not working" is experienced.

Any one of these variables, operating at an extreme, can produce a noticeable difference in HRT experience. All six operating simultaneously in the same direction produce the most dramatically variable outcomes — the women who feel dramatically better at low doses, the women who need substantially higher doses for equivalent relief, and the women who experience unexpected estrogenic effects despite apparently appropriate protocols.

What Having This Information Actually Changes

Understanding the genetic basis of HRT variability changes the conversation with your provider before, during, and after any hormone support protocol — in three specific ways:

Before starting: Knowing your ESR1 sensitivity informs whether standard initial doses are likely to achieve therapeutic receptor activation or whether your biology requires a different approach to find the effective range. Knowing your MTHFR status determines whether the folate in your supplement protocol is actually reaching your methylation cycle or passing through an impaired gate. Knowing your COMT genotype alongside your CYP1B1 activity tells your provider whether to expect straightforward clearance or a more active management of metabolic burden.

During protocol: When you and your provider are interpreting your response — whether symptom relief is adequate, whether the estradiol level on your bloodwork is landing where the biology should be responding — the genetic context changes what those numbers mean. A measured estradiol level that looks therapeutically appropriate on a population curve may be under-delivering at the receptor level if your ESR1 sensitivity is lower than average. A clearance challenge that looks like an idiosyncratic side effect may have a defined genetic explanation in slow COMT compounded by impaired MTHFR.

When something isn't working: The most common frustration in HRT management is unexplained inadequate response or unexpected effects that don't have an obvious dose-adjustment solution. Genetics provides a mechanistic framework for both. Inadequate response is often a receptor sensitivity story. Unexpected estrogenic effects are often a clearance genetics story. Genetics as a guide, not a guarantee — but a guide that replaces guesswork with defined biological context.

Test Before You Invest

The premise of the Precision Peptide Genetic Test is simple: the genetic variables that determine your individual HRT response don't change — they are fixed in your DNA and will operate the same way every time you engage with an estrogen-pathway support protocol. The choice is whether to know them before you start or to discover them through your response history. Knowing them before means your provider is working from a complete map from day one — with the genetic context to interpret your bloodwork accurately, set appropriate dose and monitoring expectations, prioritize the right supplemental support, and understand your response when it inevitably differs from the population average. The complete framework is in the Complete Guide to Genetic Women's Hormone Testing.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand the genetic variables that shape your individual HRT response? Take the Precision Peptide Genetic Test

Frequently Asked Questions About HRT Variability

Why does HRT work for some women and not others?

Six genetic variables determine how each woman processes and responds to estrogen: CYP1B1/CYP1A1 (Phase 1 metabolism), COMT and MTHFR (Phase 2 clearance), SULT1A1 and GSTM1/GSTT1 (backup clearance), and ESR1/ESR2 (receptor sensitivity). The Precision Peptide Genetic Test analyzes all 6 Reproductive Health insights across 14 pathways and 150+ genetic insights.

Can genetics explain why I need a higher HRT dose than my doctor expected?

Yes — ESR1 receptor sensitivity variants explain why some women require higher estradiol to achieve equivalent receptor activation. Lower-sensitivity ESR1 genotypes generate a weaker tissue-level response per unit of circulating estradiol — producing sub-therapeutic effects at doses that work well for higher-sensitivity women. The Precision Peptide Genetic Test identifies ESR1 within 14 pathways, 150+ insights.

Is there a genetic test that can predict how I will respond to HRT?

No genetic test predicts specific outcomes — but the Precision Peptide Genetic Test maps six variables shaping HRT response: Phase 1 hydroxylation ratio, methylation clearance speed, SAMe supply, sulfation capacity, glutathione backstop, and receptor sensitivity. That genetic baseline gives providers a more complete clinical picture than estradiol measurements alone, within 14 pathways and 150+ insights.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.